Treatments

*December 2021* Note 1: A breakthrough therapy designation is for a drug that treats a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies. Note 2: This is a potential treatment for EGFR patients after progression with osimertinib…

*December 2021* How people from different ethnic populations respond differently to treatments for a type of lung cancer called non-small cell lung cancer (also known as NSCLC). EGFR tyrosine kinase inhibitors (often shortened to EGFR TKI treatments) are a form of treatment for NSCLC called EGFR mutation-positive NSCLC. There are currently…

*January 2022* A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC WSD0922-FU for the Treatment…

*August 2020* The GioTag study assessed how drugs called afatinib and osimertinib affected people with non-small cell lung cancer (NSCLC) who had mutations in the epidermal growth factor receptor (EGFR) gene. Resistance mutations in our genes can lead to resistance to specific treatments, meaning that drugs no longer work. Patients…

*October 2021* The discovery of the EGFR driver mutation, and the subsequent development of EGFR-targeted therapy, has drastically changed the treatment and prognosis of this subgroup of patients with metastatic NSCLC. More recently, targeted therapy is also changing the treatment paradigm and outcomes for patients with early stage disease.1 Although…

*November 2021* Julie Renee Brahmer, MD, MSc, professor of oncology, co-director, Upper Aerodigestive Department, Bloomberg~Kimmel Institute for Cancer Immunotherapy, co-director, Cancer Immunology Program, director, Thoracic Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell…

*November 2021* Although next-generation TKIs, such as osimertinib (Tagrisso), have helped to overcome resistance in EGFR-mutated non–small cell lung cancer (NSCLC), a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs, as well, according to Roy S. Herbst, MD,…

*October 2021* Highlights Acquired resistance mechanisms to osimertinib can be EGFR dependent or independent. First- and fourth-generation EGFR-TKIs are able to overcome EGFR-dependent resistance. MET and MEK inhibitors may overcome EGFR-independent resistance. Anti-HER/MET novel monoclonal antibody seems effective across multiple resistance mechanisms. Carboplatin/paclitaxel ± bevacizumab/atezolizumab represents a feasible option in…